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INTRODUCTION
 Toxic thyroid nodule is the second most common 
cause of hyperthyroidism after graves’ disease.1 It is 
actually a thyroid nodule that becomes autonomous 
and results in hyperthyroidism. The autonomic 
stimulation is caused by somatic mutation in 
thyrotropin or TSH receptors in about 20-80% 
of toxic nodules and also in some multi-nodular 
goiter.2
 Toxic thyroid nodule is different from Graves’ 
disease as it is not an autoimmune disease and 
if treated adequately does not remit.3 American 
association of clinical endocrinologist and American 
thyroid association have recommended radioactive 
iodine (RAI) or surgical intervention to treat toxic 
nodular goiter.4 Surgical management although 
can cure this problem but has many anesthesia and 
surgery related complications.5 RAI is an alternative 
to surgery and is effective in treating benign nodular 
goiter.6
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ABSTRACT
Objective: To determine the outcome of patients receiving radioactive iodine therapy for toxic nodular 
goiter coming to Aga Khan University Hospital Karachi.
Methods: A total of 89 patients who visited the outpatient department of Aga Khan University Hospital 
from January 2010 to August 2017 were recruited for the study. Toxic nodular goiter was diagnosed on 
the basis of having hot nodule on thyroid scan with low TSH and high FT4/T4. Other demographic and 
laboratory data were also recorded.
Results: Eighty nine patients with toxic nodular goiter received a dose range from 10 to 30mCi RAI. Six 
months after RAI, 36.2% became hypothyroid, 38.5% became euthyroid while 25.3% remained hyperthyroid. 
Thyroid outcome at 3 months were correlating with 6 months results. 
Conclusion: Radioactive iodine therapy is a safe and effective way of treating toxic nodular goiter which 
usually results in cure of hyperthyroidism in majority of patients.
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 Treatment with a single dose of RAI usually 
achieve success in 85-100% of patients with toxic 
nodular goiter and also shrink the size of the goiter 
up to 40%7,8 RAI therapy is dependent on iodine 
uptake by the thyroid tissue and its reduce uptake 
leads to the treatment being inefficient and more 
difficult.9
 RAI therapy in toxic thyroid nodules unlike 
Graves’ disease, where majority of the patient 
becomes hypothyroid, usually result in patient 
becoming euthyroid, as the toxic nodule usually 
takes majority of radiation. Our study reported the 
outcome of RAI on toxic nodular goiter and also 
compares the accuracy of thyroid function test 
(TFTs) after 3 months of RAI as compared to six 
months.
METHODS
 A total of 89 patients with toxic nodular goiter 
who visited our outpatient department at Aga Khan 
University Hospital from January 2010 to August 
2017 were included in our study. Toxic nodular 
goiter was diagnosed on the basis of suppressed 
TSH, increase serum FT4/T4 levels and hot nodule 
on thyroid scan. Patient who were diagnosed to 
have thyroiditis or Graves’ disease were excluded 
from the study. All patients who had previous 
thyroid surgery, neck radiation or had prior RAI 
treatment were also excluded from the study. All 
those patients who were lost to follow-up were also 
omitted from the study.
 In all these patients, all the clinical information 
like age, sex, height and weight were recorded. 
Serum TSH and T4/FT4 levels were measured by 
ELISA technique. Patients who had suppressed 
TSH levels, increased T4/FT4 levels and had hot 
nodule on thyroid scan were labeled to have toxic 
nodular goiter. RAI dose was calculated clinically 
by consultant nuclear physician on the basis of 
size of thyroid nodule, thyroid function test and 
radioactive iodine uptake on thyroid scan. At each 
follow up visit, data was recorded for serum TSH 
andT4/FT4 levels after an interval of three  and six 
months.
 All of our patients were on antithyroid medication 
(Carbimazole) prior to RAI as per titration method 
according to American Thyroid Association(ATA) 
guidelines10 for the last 2-6 months and it was 
stopped five days before RAI. The thyroid status 
before RAI was also recorded as hypothyroid, 
euthyroid or hyperthyroid to access its effect on the 
post RAI outcome.
 Frequencies with percentages were reported 
for all the categorical variables in the dataset. 
Variable of Age was converted into categories 
to give a meaningful interpretation of the data 
with the outcome. Association of Pre RAI TSH 
and TSH after six months was done using Chi-
Square test statistics (expected cell count was 
greater than 5) or Fischer-Exact test statistics 
(expected cell count was less than 5). Association 
of outcome i.e. TSH after six months with age, 
gender and radioactive iodine dose was assessed 
through the same statistical tests as mentioned 
above. Comparison between three months 
and six months TSH values were also assessed 
through the same statistical test. All the analysis 
was done using Stata version 12.
RESULTS
 From January 2010 to August 2017, 89 patients 
visited Aga Khan University Hospital for toxic 
nodular goiter and were given respective radioactive 
iodine treatment. A dose of 15 and 20mCi of RAI 
was given to majority of the thyroid patients in our 
study. At six months follow-up visit, majority of 
the patients became Euthyroid (38.2%), followed 
by hypothyroid (37.0%), while 24.7% remained 
hyperthyroid.
 As all of them were on antithyroid drugs before 
getting RAI so majority of study participants, who 
were in the category of hyperthyroid, converted 
to Euthyroid at 6 months after RAI, to be precise 
36.5%. Moreover, those falling in the category of 
Euthyroid, majority of them either remained in the 
same category or shifted to hypothyroid 6 months 
after RAI, 43.8% to be precise (equal distribution 
among the two categories). For study participants 
falling in the category of hypothyroid; majority of 
them remained in the category of hypothyroid 6 
months after RAI, 50% to be precise. Overall, the 
results are not statistically significant since the 
p-value is 0.479 (calculated by Fischer Exact Test) 
(Table-I).
 The variable of age was converted into four 
meaningful categories, category one included 
study participants from 28 to 40 years, category 
two included study participants from 41 to 55 
years, category three included study participants 
from 56 to 70 years, category four included study 
participants from 71 years and above. For those 
study participants, falling in the age group of 28 
to 40 years, majority of them were hyperthyroid, 
38.9% to be precise; study participants falling in the 
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age bracket of 41 to 55 years, majority of them were 
hypothyroid, 43.8% to be precise; study participants 
falling in the age bracket of 56 to 70 years, majority 
of them were Euthyroid and hypothyroid (equal 
distribution), 37% to be precise; and finally study 
participants falling in the age bracket of 71 years 
and above, majority of them were Euthyroid, 50% 
to be precise. Overall, the results are not statistically 
significant since the p-value is 0.543 (calculated by 
Fischer Exact Test) (Table-II).
 Majority of males were falling in the category 
of hypothyroid after 6 months of RAI, 41.7% to 
be precise, majority of females were falling in the 
category of Euthyroid after 6 months of RAI, 38.8% 
to be precise. Overall, the results are not statistically 
significant since the p-value is 0.769 (calculated by 
Chi-Square Test). 
 Overall radioactive iodine dose was significantly 
associated with the outcome i.e. TFTs after 6 
months (p-value of 0.04, calculated by Fischer Exact 
Test). When a dose of 10mCi of I131 was given to the 
study participants, all remained hyperthyroid after 
6 months. When a dose of 15mCi of I131 was given 
to the study participants, 50% became hypothyroid 
after 6 months, 50.0% to be precise. When a dose of 
20mCi of I131 was given to the study participants, 
55% became Euthyroid after six months, 55% to be 
precise. When a dose of 25mCi of I131 was given to 
the study participants, 50% became hypothyroid 
after 6 months,. Finally, when a dose of 30mCi of 
I131 was given to the study participants, 66% became 
hypothyroid after six months. (Table-III).
 Study participants who were hyperthyroid at 
three months, 50% of them remained hyperthyroid 
at 6 months after RAI, to be precise 50%. Moreover, 
those who were Euthyroid at three months, 70.9% 
of them remained Euthyroid 6 months after RAI. 
For study participants, who were hypothyroid 
at three months, 67.7% remained hypothyroid 6 
months after RAI. The test statistics (Fischer Exact 
Test) p-value is < 0.001 and it is highly significant. 
This means, that the results of TFTs at three months 
do predict the accuracy of the results of TFTs at 
six months. The results of all the three different 
Radioactive iodine therapy in Toxic Nodular Goiter
Table-I: Comparison of thyroid status before and 6 months after RAI.
Thyroid Status before RAI
(on antithyroid medication)
No. (%)
Thyroid Status 6 months after RAI
Hyperthyroidism
No. (%)
Euthyroidism
No. (%)
Hypothyroidism
No. (%)
Hyperthyroidism     63(70.7) 19 (30.2) 23 (36.5) 21 (33.3)
Euthyroidism            16(17.9) 2 (12.4) 7 (43.8) 7 (43.8)
Hypothyroidism       10(11.2) 1 (10) 4 (40) 5 (50)
Overall p-value of the Table = 0.479 (Fischer Exact Test).
Table-II: Effect of age on thyroid status 6 months after RAI.
Age (Years)
Thyroid Status 6 months after RAI
Hyperthyroidism
No. (%)
Euthyroidism
No. (%)
Hypothyroidism
No. (%)
28-40 7 (38.9) 5 (27.8) 6 (33.3)
41-55 5 (15.6) 13 (40.6) 14 (43.8)
56-70 7 (26) 10 (37) 10 (37)
>71 3 (25) 6 (50) 3 (25)
Overall p-value of the Table = 0.543 (Fischer Exact Test).
Table-III: Effect of different doses of RAI 
on thyroid outcome after 6 months.
RAI 
dose
(mCi)
Thyroid Status after 6 months of RAI
Hyperthy-
roidism
No. (%)
Euthyroidism
No. (%)
Hypothy-
roidism
No. (%)
10 2 (0) 0 (0) 0 (100)
15 10 (25) 10 (25) 20 (50)
20 9 (23) 21 (55) 8 (21)
25 1 (16.7) 2 (33.3) 3 (50)
30 0 (0) 1 (33) 2 (66)
Overall p-value of the Table = 0.040 (Fischer Exact Test).
[Epub ahead of print]
Pak J Med Sci     September - October  2018    Vol. 34   No. 5      www.pjms.com.pk     4
categories are accurate and we can predict/
conclude that the results at three months and at 6 
months are somewhat similar (Table-IV).
DISCUSSION
 The analyses of our data revealed that 
hyperthyroidism was cured in majority of our 
patients, with 38.2% being rendered as Euthyroid, 
37% became hypothyroid and 24.7% remained 
hyperthyroid. The dose of RAI used was in the 
range from 10 to 30mCi. The literature is widely 
diverse with some studies showing 100% cure 
rate to 100% failure rate for hyperthyroidism. 
(Table-V) Meta-analysis of these studies showed 
that the difference of outcome depends not only 
on the RAI dose but also on multiple factors like 
size of toxic adenoma, radioactive iodine uptake, 
hyperthyroidism status prior to RAI therapy and 
Tauseef Ahmad et al.
Table-IV: Comparison between 3rd month and 6th month thyroid function test after RAI.
Thyroid Status after 3 months 
of RAI
Thyroid Status after 6 months of RAI
Hyperthyroidism
No. (%)
Euthyroidism
No. (%)
Hypothyroidism
No. (%)
Hyperthyroidism 14 (50) 9 (32.1) 5 (17.9)
Euthyroidism 4 (13.3) 19 (63.3) 7 (23.3)
Hypothyroidism 4 (13) 6 (19.3) 21 (67.7)
Overall p-value of the Table is < 0.001 (Fischer Exact Test).
Table-V: Review of literature for RAI on toxic nodular goiter.
Author Number of Patients
RAI dose 
used in mCi
Outcome
Mean year 
of follow up
Total years 
of follow upHyperthyroidism
(%)
Hypothyroidism
(%)
Blum M 
et al., 197513 14 10-15 100 - 6
Fontana B 
et al.198014 29 10-40 52 17 10 20
Eyre-Brook & 
Talbot, 198215 37 12-15 32 5.4 6.5
Goldstein & 
Hart, 198316 23 15-55 - 36 8.5 4-16.5
Ross DS 
et al., 198417 45 5-15 13.3 - 4.9±3.2 0.5-13.5
Hagedus L 
et al., 198618 27 7.5 7 - 1
Mariotti S 
et al., 198619 138 12.6±4.1 15 4 3.2±2.2 1-11
Ratcliffe GE 
et al., 198620 48 10-15 15 - 3.08 2-10
Huysmans DA 
et al., 199121 52 20 2 6 10±4 4-17.5
O.Brien T 
et al., 199222 23 19.7-100 8.7 3.5 3.8 0.4-16.3
Tzavara I 
et al., 200211 126 25-40 0 5.5 5.3±0.4 1-21
Younis J 
et al., 201523 60 20-29 0 13.3 5 4-6
Present Study 89 15-20 25.3 36.2 0.5-7
[Epub ahead of print]
Pak J Med Sci     September - October  2018    Vol. 34   No. 5      www.pjms.com.pk     5
variability between patients. We used RAI dose 
from 10 to 30mCi and our results revealed that 
although higher doses are associated with more 
hypothyroidism but it was not consistent and we 
noticed hyperthyroidism after 6 months even with 
25mCi dose of RAI. It clearly reflects that it is not 
only the dose of RAI that predict the outcome but 
other factors as mentioned above that effect the 
individual.
 Factors that might have led to these results were 
prior anti-thyroid drug treatment because less 
hyper toxic nodule has less susceptibility towards 
the RAI dose. Toxic nodule usually suppress the 
normal thyroid tissue and as they are active, it 
subsequently results in uptake of nearly all the RAI 
by the toxic nodule while the normal thyroid gland 
is saved.11 Thus complete normalization of thyroid 
function test prior to RAI may lead to higher 
incidence of developing hypothyroidism because 
of fading of this protective mechanism and it might 
have affected our results as well. It can also lead 
to incomplete destruction of toxic nodule that can 
result in persistence of hypethryoid state as one of 
our patient experienced. Large follicles also lead to 
the phenomenon of radio resistance and it is due 
to the fact that large nodule with abundant colloid 
reduces the effect of beta radiations of RAI.12
 Our study is in accordance to other studies that 
failed to show any association of age with RAI 
outcome.16 Although the subgroup analysis showed 
that the young patients up to the age of 40 years 
have increased propensity to remain hyperthyroid 
but the results were not significant. Gender also did 
not show any significant difference either. None 
of our patient developed any malignancy in the 
post RAI period and it is in agreement with the 
previous studies24 but the shorter follow up of our 
study precludes us from making any significant 
conclusion.
 The major reason for the use of RAI now a 
days instead of surgery is due to the fact that it is 
generally considered a very safe procedure and 
the malignant potential of toxic thyroid nodule is 
very less.25 The only side effect noted with RAI is 
the development of hypothyroidism that is usually 
permanent and need lifelong treatment. Previous 
long term studies have showed that if a patient 
does not develop hypothyroidism in first year, the 
chances of development in the subsequent years is 
very less.11
 We also compared post RAI thyroid function 
tests after three  and six months and the results 
showed that the 3rd month TFTs do mirror the true 
picture with accuracy (p-value < 0.001) although 
the guidelines10 still recommends 6 months TFTs 
test as the true reflection of the RAI outcome.
CONCLUSION
 In conclusion our study showed that RAI for 
toxic nodular goiter is safe and very effective 
treatment. It resolves hyperthyroidism in majority 
of patients. 
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